Aspen Pharmacare delivered a solid performance for the six months to December, having finally bedded down the last in a series of acquisitions that have seen it shift its emphasis from generics manufacturing to niche branded products. Revenue rose 11% to R21.9bn and normalised headline earnings per share increased 26% to R8.72 for the period. Aspen’s performance was driven by organic growth, particularly from its South African pharmaceutical business and its thrombosis brands. Profitability was boosted by a reversal of currency losses and by this being the first period in which its deal with AstraZeneca was fully reflected. Aspen bought the rights to AtraZeneca’s global anaesthetics portfolio with effect from September 1 2016, but only acquired the residual intellectual property rights and manufacturing know-how with effect from October 2017. “The last four years have been very busy, as we made a shift out of a generics business into what is now a predominantly speciality business,”...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.